Opus Genetics, Inc
Clinical trials sponsored by Opus Genetics, Inc, explained in plain language.
-
Gene therapy injection aims to halt rare blindness
Disease control Recruiting nowThis early-stage trial tests a gene therapy called OPGx-BEST1 in 10 adults with two rare inherited eye diseases (BVMD and ARB) that cause vision loss. The treatment is injected under the retina in one eye to see if it is safe and can slow or stop disease progression. Participants…
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New gene therapy could slow vision loss in rare childhood blindness
Disease control Recruiting nowThis study tests a gene therapy called OPGx-001 for people with vision loss caused by LCA5 gene mutations. The therapy is injected under the retina to help preserve sight. The trial includes 22 participants aged 4 and older and will check safety and whether vision stabilizes or i…
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated May 22, 2026 13:50 UTC